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------------------------------------------------------------------------------------------------------, 
To understand the basis for the anti-inflammatory activity of 
tetracyclines in acne, we compared the cytokine profiles [in-
terleukin 1 (IL-l) alpha and beta, tumor necrosis factor 
(TNF) alpha, and IL-6] and bacterial flora of 66 open come-
dones removed from eleven patients before and after at least 8 
weeks treatment with either tetracycline or minocyc1ine. 
Pre-treatment, the only cytokine regularly recovered from 
comedones was bioactive IL-1alpha-like material. The 
mean concentration ofIL-lalpha - like bioactivity / mg come-
donal material rose from 272.0 ± 88.6 pg to 844.3 ± 
196.7 pg following treatment (p < 0.05, Wilcoxon matched 
pairs). All six minocycline-treated patients showed an in-
crease in bioactive IL-lalpha -like material compared with 
three of five tetracycline-treated patients. The incidence 
(p < 0.001, X2) and concentration (p < 0.05, Wilcoxon) of 
immunochemical IL-beta were also raised post-treatment, 
although significantly more patients assigned to minocyc1ine 
therapy had detectable levels of this cytokine before therapy 
was initiated. However, the mean concentration of IL-
1beta/mg comedonal material post-treatment was similar in 
both groups (72.5 ± 23.3 pg for tetracycline-treated com, 
pared with 78.6 ± 41.9 pg for minocydine-treated patients) 
The other cytokines were either absent (IL-6) or present i~ 
< 10% of comedones (TNFalpha) before and after therapy 
Following treatment, only three of 11 patients showed ~ 
decrease of;;::: 110glO in propionibacterialnumbers/mg come. 
donal material, whereas six patients showed an increase 01 
> 0.51og1o m numbers of staphylococci. In eight patients, th~ 
increase or decrease in staphylococcal numbers correlate~ 
with the change in concentration of IL-lalpha -like bioac, 
tivity. 
This is the first study to show an effect of antibiotic theraP1-
on cytokine levels in vil/o. Increased levels of IL-l in come, 
dones destined to become inflamed may enhance resolutio~ 
and promote repair of the damaged follicular epithelium. 
Hence, these results provide further evidence of the augmen~ 
tation of immune responses by tetracyclines and support th~ 
hypothesis that epidermal IL-l plays a physiologic role i~ 
wound healing.] Invest DerrnatoI101:86-91, 1993 
-------------------------------------------------------------------------------------------------------, 
A cne vulgaris is an inflammatory disease of the pilose-baceous follicles of the face, back, and chest, charac-terized by a variety of lesions showing various degrees of visible erythema [1 J. Little is known of the inflam-matory mediators other than complement [2,3] 
present in acne lesions. Two lines of evidence, namely, the histo-
logic demonstration of non-random helper T-Iymphocyte infiltra-
tion [4J and the secretion of pro-inflammatory cytokines by kerati-
nocytes in vitro in response to a number of different environmental 
stimuli [5], suggested that the estimation of cytokines in acne lesions 
might yield information pertinent to the pathogenesis and treat-
ment of the disease. We have recen tly shown that the majority of 
open comedones contain biologically active IL-1alpha-like mate-
rial in concentrations sufficient to promote visible erythema if re-
leased into the dermis (6J . 
Successful anti-acne therapy with antibiotics is thought to be due, 
at least in part, to their inhibitory effect on the growth and metabo-
lism of Propionibacterium awes [7 -9). Micro-organisms, especially 
P. awes, have been strongly implicated in the pathogenesis of acne 
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[10,11] and may release microbial mediators of inflammation intI:< 
the dermis or trigger the release of cytokines from ductal keratino, 
cytes. However, despite clinical improvement, the numbers of pro, 
pionibacteria do not always fall during antibiotic therapy (7) . Anti, 
inflammatory activity has been proposed as an alternative a~ 
complementary mode of action of antibiotics in acne [7] and h~ 
been demonstrated ill IIillo, for both tetracyclines and erythromycil\ 
[1 2). There is currently much interest in the possible effects at 
antibiotics on cytokine production and upregulation of IL-l an~ 
IL-6 production by monocytes has been observed in vitro [13-15 ], 
The aims of this study were to determine whether oral acne theraPl' 
with tetracyclines altered the cytokine content of open comedone~ 
and to identify any concomitant changes in the comedonal micro, 
flora. 
MATERIALS AND METHODS 
Patients Open comedones (blackheads) were donated by 11 p.h 
tients with mild to moderate acne vulgaris (grade 0.5 to 3.0 on tlw 
scale of Burke and Cunliffe [16]) before and after therapy for ~ 
minimum of 8 weeks with minocycline (four male and two femal~ 
subjects, 15-29 years old, 100 mg/d), tetracycline (two male an~ 
one female, 13 -26 years old, 500 mg twice daily) or Mysteclin (one 
male, 18 years old and one female, 15 years old, tetracycline 500 mg 
twice daily plus nystatin 500,000 units twice daily). Treatment was 
selected on the basis of clinical criteria only and two patients who 
had received tetracycline previously were given Mysteclin for rea· 
sons of compliance. No patient had received any anti-acne therapy 
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for 6 weeks prior to, nor any natural ultraviolet irradiation during, 
the study. 
Recovery and Extraction of Comedones Six open comedones 
were collected aseptically from the same sample site before and after 
therapy using a comedone extractor (Thackray) after swabbing the 
skin surface with isopropanol. Four patients were sampled from the 
face and seven the back. No sample was obviously contaminated 
with blood. The wet weight of each comedone was determined 
prior to gentle homogenization for 1 min in a micro-tissue homo-
genizer (Thackray) in 250 III of Dulbecco's modified Eagle's me-
dium supplemented with 2 mM L-glutamine, 0.375% (w Iv) 
NaHC03, 20 mM Hepes, and 10% (v/v) fetal calf serum. The 
homogenate was centrifuged (10,000 X g; microfuge; MSE Micro-
centaur) for 10 min. The supernatant (approximately 230 Ill) was 
removed and diluted 1: 10 with base medium containing penicillin 
(100,000 V/I) and streptomycin (100 mg/I), aliquotted and stored 
at -20°C for the determination ofbioactive and immunochemical 
IL-l alpha and beta. The pellet was resuspended in 200 III of wash 
fluid (0.075 M sodium phosphate buffer containing 0.1 % v /v Tri-
ton-XI00, pH 7.9) for microbiologic determinations. 
Cytokine Bioassays Bioactive IL- lalpha and beta were esti-
mated as previously described using a modification of the C3H 
murine thymocyte proliferation assay in the presence of saturating 
levels of IL-2 [6]. Specificity was accomplished by pre-incubating 
the supernatants in the presence and absence of anti - IL-lalpha and 
anti-IL-1beta antibodies (British Biotechnology) separately and 
together prior to assay. Allowing for the dilution of the comedonal 
material in the assay, the sensitivity of the IL-l bioassay was 10 
pg/comedone. Bioactive TNFalpha was estimated using a conven-
tional L929 cytotoxicity assay as previously described [6] and the 
lower limit of detection was 50 pg TNFalpha/ comedone. Bioactive 
IL-6 was quantified by the method of van Oers et al [17] using 
IL-6-dependent B9.9 hybridoma cells and substituting MTT con-
version instead of 3H-thymidine incorporation as a measure of cell 
viability. All bioassays were validated "in house" for use with come-
donal material as described in our previous report [6]. 
Cytokine Immunochemical Assays Immunochemical IL-
lalpha, TNFalpha, and IL-6 were determined using Quantikine 
enzyme-linked immunosorbent assay kits (British Biotechnology). 
The sensitivity of the kits varied between 17 and 31 ng/I (170-310 
pg/comedone) for IL-lalpha, and between 31-48 ng/l (90 pg/ 
comedone) for TNFalpha and IL-6. IL-l beta was determined using 
Cistron enzyme-linked immunosorbent assay kits supplied by T-
cell Sciences. The sensitivity was 4 ng IL-l beta/I (20 pg/ come-
done). All assays were carried out according to the manufacturers' 
instructions. 
Enumeration of Microorganisms Staphylococci and propion-
ibacteria were enumerated in the pellets from the centrifugation of 
comedonal homogenates after resuspension in wash fluid . Viable 
counts [expressed as colony-forming units (cfu)] were carried out as 
previously described [6]. The lower limit of detection was 4 cfu/ 
comedone. 
Statistical Analyses These were carried out according to the 
recommendations of Sokal and Rohlf[18]. 
RESVLTS 
Effect of Therapy on Acne Grade Acne is a slowly responding 
disease and the patients were deliberately sampled early (i.e., approx-
imately one third of the way through a standard 6-month course of 
treatment) to determine the likely initial events leading to clinical 
improvement. At the time of sampling, two of the 11 patients had a 
> 50% improvement in their acne grade (both on minocycline), 
four had an improvement of < 50% (two on minocycline and two 
on tetracycline), one tetracycline-treated patient experienced a 
marked deterioration in acne severity that necessitated a change of 
therapy, and the remainder showed no detectable change. At the 
end of the standard 6-month course, four of six minocycline-treated 
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Table I. Changes in Comedonal Weight Following Treatment 
Mean Weight of Comedones 
(mg) ± 95% Confidence Limits' 
Treatment Group 
Minocycline (n = 36)' 
Tetracycline (n = 30) 
All patients (n = 66) 
Pre-Treatment 
0.86 ± 0.43 
0.90 ± 0.49 
0.88 ± 0.30 
• Calculated from student t X SEM. 
• Student t tcst. NS, non significant (p > 0.05) . 
, Number of comedones. 
Post-Treatment 
0.93 ± 0.77 
0.63 ± 0.29 
0.79 ± 0.42 
p Valueb 
NS 
NS 
NS 
patients were showing a > 50% improvement in acne grade, one 
patient showed a < 50% improvement, and one patient failed to 
return for their final assessment. Two of five tetracycline-treated 
patients were showing a < 50% improvement at 6 months, one had 
withdrawn from the study (see above), and two failed to return for 
follow-up appointments. 
Effect of Therapy on Comedone Weight There was no signif-
icant difference (Student t test) between the weight of the come-
dones before and after treatment with either minocycline or tetracy-
cline although there was reduction of 30% in the mean comedonal 
weight following tetracycline treatment (Table I). 
Effects of Therapy on Bacterial Numbers Changes in pro-
pionibacterial numbers were minimal with only three of 11 patients 
showing a ~ 1 loglo reduction in mean count expressed as cfu/mg 
comedonal material after at least 8 weeks oral therapy with either 
minocycline (Fig 1) or tetracycline (Fig 2). Changes in staphylococ-
cal numbers varied from individual to individual but surprisingly six 
of 11 patients showed an increase of > 0.5 loglo (Figs 1 and 2). 
Overall, there was no change in the mean counts of staphylococci or 
propionibacteria following treatment with either antibiotic (Table 
II). Pre-treatment, 37% of comedones were not colonized (i.e., 
< 10- 2 cfu/mg) by staphylococci and 34% were not colonized by 
propionibacteria. Following treatment, there was no alteration in 
the proportion of uncolonized follicles: 39% were not colonized by 
staphylococci, and 36% were not colonized by propionibacteria. 
Effect of Therapy on Cycokine Levels Bioactive IL-lalpha -
like material was detected in 76.9% of open comedones before 
treatment and in 75.8% after treatment. However, the mean con-
centration of IL-lalpha -like bioactivity per mg comedonal weight 
was significantly increased post-treatment in minocycline-treated 
patients (p < 0.01, Fig 1) and when data from both treatment 
groups were combined before analysis [p < 0.05, Wilcoxon 
matched pairs (Table III)]. In eight patients (three of six on minocy-
cline and five of five on tetracycline), the increase or decrease in 
IL- lalpha-like bioactivity corresponded with an increase or de-
crease in numbers of staphylococci (Figs 1 and 2) . Bioactive IL-
l beta was not detected before or after therapy with either antibiotic. 
Following treatment, the incidence ofimmunochen'lically detect-
able IL-lalpha rose from 12.1% to 28.8% of comedones and the 
mean concentration/mg comedonal material was significantly 
raised [p < 0.05, Wilcoxon (Table IV)] . Both the incidence (p < 
0.001, X2) and mean concentration/mg comedonal material (p < 
0.05, Wilcoxon) of immunochemical IL-lbeta rose significantly 
post-treatment when data from both treatment groups were com-
bined (Table V). The greatest increases were recorded in tetracy-
cline-treated patients. This difference between treatment groups 
was due to the significantly higher baseline incidence of immuno-
chemical IL-lbeta-containing comedones in the group assigned to 
minocycline therapy (p < 0.001, X2). In this group, all six come-
dones from two patients contained immunochemical IL-l beta be-
fore therapy was initiated. However, the incidence and mean con-
centration of immunochemical IL-l beta post-treatment was similar 
in both treatment groups (Table V). 
TNFalpha-like bioactivity was detected in 4.5% of comedones 
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Figure L Effect of minocycline therapy on IL- l alpha - like bioactivity (A) 
and on vIable counts of staphylococci (B) and propionibacteria (C) per mg 
comedonal materia l. Each pair of bars shows the mean ± 95% confidence 
limits (Student t X SEM) for six open comedones collected from each pa-
tient before (II) and after (0) treatment. 
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Figure~. Effect of tetracycline therapy on IL-l alpha - likc bioactivity (A) 
and on vIable counts of staphylococcI (B) and propionibacteria (C) per mg 
comedonal material. Each pair of bars shows the mean ± 95% confidence 
limits (Student t X SEM) for six open comedones collected from each pa-
tient before (II) and after (0) treatment. 
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Table II. Microbial Numbers Before and After Antibiotic Therapy 
logto cfu/ m g Comedonal Material 
Number of % Mean' ± 95% 
Micro-Organism Therapy Comedones Positive Range" Confidence Limi ts' 
Staphylococci Pre-treatment Minocycline 
Post-treatment 
Propionibacteria Pre-treatment Minocycline 
Post-treatment 
Staphylococci Pre-treatment T etracycline 
Post-treatment 
Propionibacteria Pre-treatment Tetracycline 
Post-treatment 
• Range of positive values. 
, Mean for all comedones. 
, Calculated from Student t X SEM. 
pre-treatment and in 6.1 % of comedoI?es following treatment. Im-
munochemical TNFalpha was present 111 9.1 % of comedones before 
treatment but was not detected following treatment. Immunochem-
ical IL-6 and IL-6 bioactivity were undetectable both before and 
after treatment. 
DISCUSSION 
The tetracycline antibiotics are used extensively in the therapy of 
acne vulgaris. Although the.y i~hib~t ~he gr?wth of Propi?/Iibacl~r­
ium acnes both in vitro and III VIVO, It IS un!tkely that antibacterial 
activity alone is ~esponsible for their therapeutic. efficacy bec~u~e 
better antimicrobial agents such as benzoyl perOXide are less c!tnt-
cally effective [1 9,20]. Both tetracycline and erythromycin have 
been shown to reduce l20tassium iodide - induced cutaneous inflam-
mation in human skin l1 2]. In vitro, the tetracyclines exert a number 
of effects on host defense mechanisms such as the down regulation 
of cell-mediated immune responses and the inhibition of neutrophil 
functions [21-25]. More recently, we have shown that minocycline 
and to a lesser extent, tetracycline enhanced IL-l beta secretion by 
LPS-stimulated mononuclear cells from five different donors [14]. 
Therefore, it appears that there are a number of possible mecha-
nisms whereby the tetracyclines could modulate immune responses 
and hence inflammation in vivo. However, evidence to show that 
the tetracyclines interfere with any of these physiologic processes 
during therapeutic use has been lacking. 
We have previously demonstrated the presence of bioactive IL-
lalpha-like material in the majority (76%) of open comedones 
from untreated acne patients [6] . The identity of the comedonal 
mediator with monocyte-derived IL-lalpha has not been con-
firmed; we have followed the recommendation of Camp et at [26] 
and referred to the activity as IL-lalpha - like. We have now shown 
that treatment with tetracycline antibiotics upregulates the produc-
35 80 1.00 - 6.36 3.82 ± 0.78 
36 83.3 1.1 2 - 6.6 1 3.37 ± 0.75 
35 80 1.30 - 6.77 4.20 ± 0.88 
36 83.3 0.70 - 7.21 4.11 ± 0.84 
30 76.7 0.32 - 5.84 2.40 ± 0.77 
30 80 0.90 - 6.33 2.56 ± 0.72 
30 83.3 0.90 - 6.79 2.67 ± 0.82 
30 70 1.06 - 6.53 2.68 ± 0.92 
tion ofbioactive IL-1 alpha - like material and immunochemical IL-
Ibeta. As in our earlier study , we found no correlation between 
bioassay and immunoassay data for IL-lalpha, suggesting possible 
differences in the epitopes expressed by the skin-associated and the 
monocyte-derived cytokine. However, the activity in the IL-l 
bioassay was completely neutralized by anti - IL-lalpha antibody. 
The observed increase in com.edonal IL-l is difficult to reconcile 
with the anti-inflammatory effects of the tetracyclines because IL-l 
is usually considered to be a pro-inflammatory cytokine. Camp et at 
have already demonstrated that the injection of ~ 100 pg of IL-
lalpha - like material from human skin prom.otes dose-related visi-
ble erythema lasting up to 48 h [26]. Using this criterion, 58.5% of 
comedones removed pre-treatment and 65.2% removed post-treat-
ment contained sufficient IL-l alpha- Iike material (> 100 pg/mg) 
to promote visible inflammation if released into the dermis follow-
ing spongiosis or rupture of the follicle wall. Furthermore, the mean 
concentration of IL-lalpha - like material was four times higher 
following therapy. In follicles in which the initial stimulus (still 
unidentified but possibly bacterial) has set the inflammatory cascade 
in motion, the normal chain of events leading to eventual resolution 
of the lesions will occur irrespective of whether treatment inter-
venes. The enhancement ofIL-l production within such follicles by 
tetracycline therapy may accelerate resolution by decreasing both 
the extent and duration of the inevitable inflammatory stage of the 
disease. In normal follicles, in which there is no breach in the folli-
cle wall, increased levels of IL-1 resulting from antibiotic therapy 
will be sequestered within the duct and thus unable to promote 
inflammatory changes. IL-1 is also recognized to play a role in 
wound healing following thermal or traumatic damage to the epi-
dermal barrier [27,28] and may thus facilitate repair of the damaged 
follicular epithelium. On the other hand, modulation ofIL-l levels 
may not be related to the anti-i nflammatory action of the tetracy-
Table III. Levels of Bioactive IL-lalpha - like Material before and After Treatment 
pg IL-lalpha/mg Comedonal Material 
Number of % 
Therapy Comedones Positive Range' 
Pre-treatment Minocycline (n = 6)J 36 91.7 31-1170 
Post-treatmen t 36 77.8 41- 11050 
Pre-treatment Tetracycline (n = 5) 29 58.6 23 - 1750 
Post-treatment 30 73.3 51 - 11 27 
Pre-treatment All patients (n = 11) 65 76.9 23 - 1750 
Post-treatment 66 75.8 41 - 11050 
• Range of positive values. 
• Mean for all comedones. 
, Calculated from Student t X SEM. 
'Number of patients in each group. IL-lalpha - like bioactivity was measured in six open comedones extracted from each patient 
'J Post-treatment means were significantly higher than pre-treatment means for minocycline-treated patients (p < 0.01 ') and when ( 
analysis (p < 0.051', Wilcoxon matched pairs). 
Meanb ± 95% 
Confidence Limits' 
308.2 ± 101.8 
1267.2 ± 695.2' 
227.0 ± 158.6 
336.9 ± 137.4 
272.0 ± 88.6 
844.3 ± 196.71 
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Table IV. Levels of lmmunochemical IL-1alpha Before and After Treatment 
Number of % 
Therapy Comedones Positive 
Pre-treatment Minocycline (n = 6)J 36 16.7 
Post-treatment 36 36.1 
Pre-treatment Tetracycline (n = 5) 30 6 .7 
Post-treatment 30 16.7 
Pre-treatment All patients (n = 11) 66 12.1 
Post-treatment 66 28.8 
"' pg IL-l al pha/ mg Comedonal Materia'! 
"' Meanb ± 95% 
Range' Confidence Limits\ 
"' 119 - 427 47.3 ± 38.8 
78 - 2040 239.4 ± 174.4 
279 - 377 21.9 ± 31.4 
148 - 1020 72.07 ± 75 .2 
119 - 427 35.7 ± 25.1 
78 - 2040 163.3 ± 101.1 ' 
---
• Range of positive values. 
b Mean for all comedones. Comedones in which the level of Ilo 1 alpha was below the detection limit were considered not to contain the cytokine. 
, Calculated from Srudent t X SEM. 
i Number of patients. 
'The concentration of IL-laipha was significantly higher post-treatment when data from both groups were combined before analysis (p < 0.05, Wilcoxon matched pairs) . 
clines, which cou ld instead be mediated by one of several other well 
documented effects on cellular immunity (vide supra) or could be a 
secondary consequence of changes in microbial numbers (vide i /lfra). 
In a previous study, we found an association between the lower 
limit of microbial density and comedonal levels of IL-lalpha-like 
bioactivity although there was no evident correlation between 
numbers of individual microbial species and concentrations of this 
cytokine [6] . In addition, three comedones that contained no micro-
organisms contained no detectable IL-1alpha-like bioactivity. We 
believed that any real relationship that may exist between microbial 
numbers and cytokine content of open comedones might be re-
vealed by concomitantly measuring changes in both variables as a 
result of antibiotic therapy. We confidently expected numbers of 
propionibacteria to fall based on our own previous data [9] and those 
of others [8]. Leyden et al [8] measured decreases of> 2 loglo in 
propionibacteria I numbers in follicular casts following 6 weeks of 
oral therapy with either 1000 mg of tetracycline or 200 mg of mino-
cyeline. In the present study, we found no overall decrease in 
numbers of propionibacteria/mg comedonal material following ~ 8 
weeks of oral therapy with an equivalent dose of tetracycline or 
100 mg minocyeline. The reasons for this difference are unelear. It 
is possible that bacteria in acne lesions respond more slowly to 
antibiotic therapy than surface organisms or those in normal folli-
cles due to interference with antibiotic penetration by hypercornifi-
cation and blockage of the follicular opening. Paradoxically, staphy-
lococcal numbers increased during therapy in six of 11 patients and 
in eight patients the increase or decrease in staphylococcal numbers 
correlated with a corresponding increase or decrease in the concen-
tration of IL-1alpha-like bioactivity. Therefore, comedonallevels 
ofIL-1alpha-like bioactivity may, at least in part, be determined by 
staphylococcal and not propionibacteria I population densities. This 
possibility is supported by the demonstration that as few as 10 cells 
per monocyte of "Staphylococcus albus" (now Staphylococcus epiderm i-
dis) stimulated production of high levels ofIL-l in culture [29]. We 
must be careful not to overinterpret our preliminary observations, 
which are based on the measurement of bacterial densities and cyto_ 
kine levels at one time point only. It would be pertinent now to 
follow the changes in IL-1 concentration and microbial numbers at 
several time points during a standard 6-month course of therapy. In 
this way we should obtain a much clearer picture of how the 
changes resulting from treatment with the tetracyclines relate to 
each other, to the therapeutic outcome, and to the anti-inflamma-
tory effects of the antibiotics . 
The cellular origin of the IL-1 detected in acne comedones was 
not investigated in the present study. The major species of IL-l 
found in normal human epidermis appears to be IL-1alpha [30,31]. 
Cultured human keratinocytes secrete bioactive IL-lalpha but not 
beta, whereas monocytes secrete both cytokines in a bioactive form 
[32]. Keratinocytes secrete inactive IL-l beta because they lack the 
necessary proteinase to convert it into the active form [32]. There-
fore, the increase in bioactive IL-l alpha and immunodetectable but 
biologically inactive IL-l beta fo llowing treatment with tetracy-
clines is consistent with their production by ductal keratinocytes. 
As far as we are aware, this is the first report to demonstrate an 
effect of antibiotic therapy on cytokine levels i,1 vivo. Whether or 
not modulation of IL-l production contributes to the therapeutic 
efficacy of the tetracyclines in acne cannot be predicted from the 
results of this study. The demonstration of a wide range of effects of 
so-called "antibacterial" antibiotics in physiologic concentrations 
on a variety of functions in eukaryotic cells should at least lead to a 
Table V. Levels of Immunochemical IL-l beta Before and After Treatment 
pg IL-1beta/mg Comedonal Material 
Number of % 
Therapy Comedones Positive Range' 
Pre-treatment Minocycline (n = 6)J 36 52.8' 14 - 104 
post-treatment 36 83 .3 4.3 - 540 
Pre-treatment Tetracycline (11 = 5) 30 0' 
Post-treatment 30 93.31 18 - 270 
Pre-treatment All patients (n = 11) 66 28.8 14 - 104 
post-treatment 66 87.91 4.3 - 540 
• Range of positive values. 
b Mean for all comedones. Comedones in which the level of IL-I beta was below the detection limit were considered not to contain the cytokine. 
, Calculated from Student t X SEM. 
i Number of patients. 
, The number of comedones containing IL-1 beta pre-treatment was higher in the group assigned to minocycline therapy (p < 0.00 I, X2). 
Meanb ± 95% 
Confidence Limits' 
22.7 ± 9.4 
78.6 ± 41.9 
72.5 ± 23.3 
12.4 ± 5.8 
75.9 ± 24.7x 
IThe number of comedones containing IL-lbeta was significantly higher post-treatment in tetracy.cline-treated patients and when data from both groups was combined before 
analysis (p < 0.001, X2 ) . 
• The concentration ofIL-lbeta was significantly higher post-treatment when data from both groups were combined before analysis (p < 0.01, Wilcoxon matched pairs). 
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reaypraisal of their mode of action in the therapy of acne and other 
inflammatory dermatoses. 
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